Impact of a patient-derived hepatitis C viral RNA genome with a mutated microRNA binding site

Miguel Mata¹, Steven Neben², Karim Majzoub¹,³, Jan Carette¹, Muthukumar Ramanathan⁴, Paul A. Khavari⁴, Peter Sarnow¹*

¹ Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, United States of America, ² Regulus Therapeutics, San Diego, CA, United States of America, ³ INSERM U1110, Institute of Viral and Liver Disease, University of Strasbourg, France, ⁴ Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, United States of America; Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, United States of America

* psarnow@stanford.edu

Abstract

Hepatitis C virus (HCV) depends on liver-specific microRNA miR-122 for efficient viral RNA amplification in liver cells. This microRNA interacts with two different conserved sites at the very 5’ end of the viral RNA, enhancing miR-122 stability and promoting replication of the viral RNA. Treatment of HCV patients with oligonucleotides that sequester miR-122 resulted in profound loss of viral RNA in phase II clinical trials. However, some patients accumulated in their sera a viral RNA genome that contained a single cytidine to uridine mutation at the third nucleotide from the 5’ genomic end. It is shown here that this C3U variant indeed displayed higher rates of replication than that of wild-type HCV when miR-122 abundance is low in liver cells. However, when miR-122 abundance is high, binding of miR-122 to site 1, most proximal to the 5’ end in the C3U variant RNA, is impaired without disrupting the binding of miR-122 to site 2. As a result, C3U RNA displays a much lower rate of replication than wild-type mRNA when miR-122 abundance is high in the liver. This phenotype was accompanied by binding of a different set of cellular proteins to the 5’ end of the C3U RNA genome. In particular, binding of RNA helicase DDX6 was important for displaying the C3U RNA replication phenotype in liver cells. These findings suggest that sequestration of miR-122 leads to a resistance-associated mutation that has only been observed in treated patients so far, and raises the question about the function of the C3U variant in the peripheral blood.

Author summary

With the advent of potent direct-acting antivirals (DAA), hepatitis C virus (HCV) can now be eliminated from the majority of patients, using multidrug therapy with DAAs. However, such DAAs are not available for the treatment of most RNA virus infections. The main problem is the high error rate by which RNA-dependent RNA polymerases copy viral RNA genomes, allowing the selection of mutations that are resistant to DAAs. Thus, targeting host-encoded functions that are essential for growth of the virus but not...
for the host cell offer promising, novel approaches. HCV needs host-encoded microRNA miR-122 for its viral RNA replication in the liver, and depletion of miR-122 in HCV patients results in loss of viral RNA. This study shows that a single-nucleotide mutation in HCV allows viral RNA amplification when miR-122 abundances are low, concomitant with changes in its tropism.

**Introduction**

Many cell- and virus-encoded microRNAs (miRNAs) regulate the expression of mRNAs by binding to the 3’ noncoding regions of target mRNAs. The binding is facilitated by an RNA-induced silencing complex (RISC) that mediates base-pair interactions between nucleotides two through seven in the microRNA (seed sequences) and their complementary sites in the target mRNA (seed-match sequences). This targeting event inhibits the translation of the mRNA. In addition, deadenylation at the 3’ of the mRNA, followed by decapping and 5’ to 3’ degradation of the mRNA greatly increases its turnover [1, 2].

The growth of hepatitis C virus (HCV), a member of the flaviviridae, is dependent on the most abundant miRNA in the liver, miR-122 [3]. In the liver, miR-122 is known to be crucial for upregulation of cholesterol metabolism [4, 5]. In the HCV genome, we discovered two binding sites for miR-122 at the 5’ proximal end of the viral RNA [3]. Occupancy of both sites by miR-122 is required for the maintenance of viral RNA abundance in infected liver cells [3, 6–8]. Loss of HCV RNA abundance could be observed when HCV-infected cells were treated with modified oligonucleotides that have base-pair complementarity to miR-122 (miR-122 anti-miRs) [3]. HCV sequences termed site 1 and site 2 are seed-match sequences for miR-122 and are both absolutely conserved among all genotypes of HCV and present in all HCV gene sequences from patients deposited in gene banks. Deleterious effects of mutations in either miR-122 binding site 1 or site 2 on HCV RNA accumulation can be rescued by co-transfection of mimetic miR-122 duplexes that targeted the mutated HCV genomes [3, 6] [7]. Thus, HCV subverts host miR-122 to increase its expression in liver cells. It is envisaged that HCV RNA genomes have evolved to bind the highly abundant liver-specific miR-122 [9] to guarantee persistence in the liver over many years. Mechanistically, miR-122 has been shown to protect the 5’ ppp-containing HCV genome from the action of 5’ RNA triphosphatase DUSP11 [10, 11] and subsequent degradation by 5’ RNA exonucleases XRN1 [12] and XRN2 [13]. In addition, miR-122 has been shown to enhance translation initiation of the downstream located internal ribosome entry site (IRES) [14] [15] by a mechanism that involves in the proper folding of the IRES [16]. Further evidence suggests that miR-122 also participates in the switch of viral RNAs from the translation to the replication phase in the viral life cycle by displacing of RNA binding proteins that enhance viral mRNA translation [17].

Clinical applications of miR-122 anti-miRs first showed that sequestration of miR-122 in mice [4, 5] and in non-human primates [18] lowered plasma and liver cholesterol abundance without any obvious adverse effects on liver function. Subsequently, Lanford and colleagues [19] tested the effects of sequestration of miR-122 after intravenous administration of unformulated locked nucleic acids (LNAs)-containing miR-122 anti-miRs in HCV-infected chimpanzees. Administration of LNAs caused a 500-fold reduction of viral titer in both serum and liver that persisted for several weeks. Encouraged by these results, independent studies evaluated the efficacy of two different miR-122 anti-miRs, miraviren [20] and RG101 [21], in patients with chronic HCV genotype 1 infections. Treated patients showed a 10–1000 fold reduction in viral serum titers. While the majority of the patients cleared the infection, several
subjects in both studies experienced a virologic rebound several weeks after anti-miR treat-
ment [21, 22]. Sequence analysis of viral RNAs obtained from serum of several of those
patients revealed a resistance-associated substitution of a uridine for a cytidine nucleotide 3
(C3U) [20, 21]. The goal of the present study was to examine whether the C3U mutation truly
confers resistance to miR-122 anti-miRs and to determine the mechanism of any such escape,
to provide a basis for investigation whether these variants will compromise clinical treatments.

Results
C3U HCV RNA replicates with higher efficiency than wild-type HCV RNA
during miR-122 sequestration
Sera from five out of six HCV patients whose viral titers rebounded following miR-122 anti-
mir treatment contained HCV genomes with a C3U mutation. Two patients contained a
C3U/C27U or C3U/G28A double mutation, respectively [21]. These findings suggested that
the C3U RNA variant may replicate with higher efficiency than wild-type RNA in liver cells
when miR-122 is sequestered, and thus represent a drug-resistant variant.

To test this hypothesis, in vitro-synthesized wild-type and C3U Gaussia luciferase-express-
ing H77S.3/GLuc viral RNAs (Fig 1A) [23] were transfected into Huh7.5 cells that had previ-
ously been treated with non-122 targeting control anti-miR-106b-LNA (locked nucleic acids),
anti-miR-122-LNA miravirsen [22], or anti-miR-122 RG1649 (the active metabolite of RG101)
[21], and HCV RNA replication was monitored. Anti-miR-122 inhibitors miravirsen and
RG101 were used, because both compounds were shown to lower HCV abundances in clinical
trials [21, 22]. Fig 1B shows effects of miR-122 LNAs and RG1649 RNA abundances of wild-
type and C3U RNAs, as reflected by the accumulation of luciferase encoded in the viral
genome. GLuc activity was normalized to GLuc activity measured in the presence of control
miR-106b LNA. This was done, because the overall C3U RNA abundances were lower than
WT in control-LNA transfected cells (see data without normalization in S1 Fig). Wild-type
HCV RNA accumulation was reduced relative to C3U HCV in miR-122 cells, which were
fused with miR-122 LNA or RG1649 after 24 and 48 hours (Fig 1B, S1 Fig). These findings
argue that reduced abundance of miR-122 is less inhibitory to the growth of C3U HCV, thus
rationalizing the emergence of the C3U genome in anti-miR-treated patients.

To determine whether the C3U mutation acts by increasing the abundance of HCV RNA
following miravirsen-mediated sequestration of miR-122, the accumulation of newly synthe-
sized viral RNA was measured by labeling with 5-ethynyl uridine (5-EU), an analog of uridine.
Total RNA was isolated and conjugated to biotin in a copper-catalyzed reaction. Newly synthe-
sized RNA was subsequently captured using magnetic streptavidin beads and quantitated by
qRT-PCR using HCV-specific primers. While the abundance of wild-type RNA synthesis was
reduced by ~80% in miravirsen-treated samples, only a 30% reduction was observed in C3U
variant samples following miR-122 depletion compared to control miR-106b-LNA treatment
(Fig 1C).

To determine whether the binding of miR-122 molecules to the C3U HCV genome plays
any role at all in its replication, infectious RNAs were transfected into miR-122 knock-out
Huh7.5 cells [24] that were pre-transfected with control duplex miR-106b or native miR-122
duplexes. Exogenously added control duplex failed to rescue the greatly reduced abundance of
either wild-type or C3U RNA. Supplementation of miR-122 duplexes enhanced the amplifica-
tion of both wild-type and mutant viral RNAs, albeit C3U to a significantly lesser extent than
wild-type RNA (Fig 1D). These results argue that C3U RNA requires at least a small amount
of miR-122. It is known that miR-122 has different affinities to site 1 and 2 in HCV RNA [25].
Thus, different affinities for miR-122 at site 1 or site 2 in both C3U and wild-type RNAs could explain the observed phenotype.

To test this hypothesis, C3U-complementary duplex miR-122 molecules (referred to as “mut-miR-122”) were employed to monitor C3U RNA replication phenotypes in cells that expressed no wild-type version of miR-122. Again, pre-treatment with miR-106b RNA mimetics did not rescue replication of wild-type or C3U viral RNAs (Fig 1E). As was also expected, supplementation of C3U with mut-miR-122 efficiently enhanced C3U RNA abundance. That both wild-type and mutant miR-122 can rescue the C3U genome
to some extent, but neither as completely as native miR-122 rescues the wild-type genome, suggests that both wild-type and mutant miR-122 might bind to the C3U genome.

To substantiate this finding further, miR-122 knock-out cells were pre-transfected with wild-type and mut-miR-122 duplexes alone or in combination and abundances of transfected infectious RNAs were monitored over time. Co-transfection of both wild-type and mut-miR-122 had minimal additive effect on the accumulation of wild-type HCV RNA compared to transfection of wild-type miR-122 alone (Fig 1F). In sharp contrast, accumulation of the C3U variant was significantly enhanced in the presence of combined wild-type and mut-miR-122 mimetics compared to the presence of either alone (Fig 1F). Analysis of viral infections by Northern blot analyses (Fig 1G) revealed the same phenotypes. These data show that a single C3U nucleotide substitution in the 5’ noncoding region of the HCV genomic RNA, where miR-122 occupies binding site 1, results in increased resistance to miR-122 sequestration. Because HCV RNA accumulation in a C3U background could be effectively rescued only by a combination of native and mutant-miR-122 mimetics, sites 1 and 2 in C3U RNA are likely occupied by mutant and wild-type miR-122, respectively, and occupancy of both is required for its optimal function. This situation is not likely to be obtained under any circumstance in liver cells, leading us to question whether the C3U mutation might bring about a large fitness cost to viruses that contain it.

C3U mutation in HCV RNA reduces viral fitness in Huh7 liver cells

To investigate the impact of the C3U HCV mutation on viral fitness in liver cells when miR-122 abundance is normal, in vitro-synthesized wild-type and C3U H77.S3 infectious RNAs [23] were electroporated into Huh7.5 liver cells [26]. At different times after electroporation, supernatants were collected and extracellular HCV titers were determined by fluorescent focus forming units (FFU) measurements after infection of Huh7.5 cells (Fig 2A). In contrast to wild-type virus-infected cells, which reached a maximum of $10^3$ FFU/ml, virus yield was ten-fold lower in cells infected with C3U HCV virus (Fig 2A).

Next, viral spread was examined by infecting naïve Huh7.5 cells with wild-type and mutant viruses. Supernatants were collected three days post-infection and quantified by FFU assays. Similarly, to the data shown in Fig 2A,
viral production (Fig 2B) and RNA accumulation (Fig 2C) after these multiple cycles of infection were ten-fold lower in C3U HCV-infected compared to wild-type HCV-infected cells. Thus, the C3U mutation results in a significant reduction in mutant viral RNA and virion abundances at a step that does not involve viral entry.

**C3U mutation leads to reduced viral RNA replication in liver cells**

To measure the effects of the C3U mutation on viral mRNA translation and RNA replication, in vitro-synthesized wild-type and C3U *Gaussia* luciferase-expressing H77S.3/GLuc viral RNAs (Fig 1A) were transfected into Huh7.5 cells and luciferase activities were examined at different times after transfection. Replication of the C3U viral RNA was ten-fold lower than that of wild-type RNA between 48 and 72 hours after transfection (Fig 3A). Similar to the phenotype observed with luciferase activities, Northern blot analysis revealed a decrease of C3U RNA abundance compared to wild-type viral RNA at three days after RNA transfection (Fig 3B). Both wild-type and mutant RNAs were sensitive to the HCV RNA polymerase NS5B inhibitor sofosbuvir (Fig 3B), demonstrating that authentic viral RNAs were inspected in the

![Fig 3](https://doi.org/10.1371/journal.ppat.1007467.g003)
Northern blots and that the C3U variant can be eliminated by sofosbuvir. The effect of the C3U mutation was not genotype-specific, because insertion of the C3U mutation into the J6/JFH1 RLuc genotype 2a infectious background also resulted in significant reduction in RNA replication (S2 Fig). In addition, the effects of a G28A mutation on RNA abundances of transfected, chimeric C3-G28A and C3U-G28A were examined. This mutation, which is predicted to engage in base-pair interaction of nucleotide number one of miR-122 at site 2, was detected in Huh7 cells during mir-122 sequestration [27–29] and in the blood of HCV-positive patients [29]. S3 Fig shows that the G28A mutation had no effect on the replication of HCV RNAs lacking a C3U mutation. This finding agrees with Israelow et al. [27] who reported that G28A virus replicates with similar efficiency than wild-type virus in the presence of miR-122, but more efficiently than wild-type virus when miR-122 is limiting. However, chimeric C3U-G28A RNAs replicated with similar efficiency as C3U RNAs (S3 Fig), arguing that the observed phenotype depends on the single C3U nucleotide change. Finally, the abundance of viral core protein was also reduced in C3U RNA-transfected cells at 72 hours compared to wild-type RNA (Fig 3C), suggesting defects in protein synthesis, RNA replication or RNA stability in C3U HCV.

To examine in detail whether reduced translation or replication contributed to low viral RNA abundances in C3U RNA-transfected cells, we studied the expression of chimeric RNAs, containing GDD-to-AAG mutations in the active site of viral RNA-dependent polymerases NS5B in both wild-type and C3U RNAs. Fig 3D shows that translation, RNA stability, or both of the C3U variant was similar to wild-type at all time points measured, arguing that the growth defect of C3U HCV is predominantly at the replication step. To examine effects of the C3U mutation on HCV translation by a different approach, polysomal mRNAs were analyzed from HCV RNA-transfected cells after separating cell lysates in sucrose gradients. The distribution of full-length HCV RNA in each individual fraction was analyzed by Northern blot analysis (S4A Fig). HCV RNA was distributed in polysomal fractions 9 through 13 in both wild-type- and C3U-transfected samples (Fig 4A and 4B). These data suggest that the observed reduced intracellular RNA abundance of C3U HCV is primarily due to a defect in RNA replication or stability.

Effects of the C3U substitution on viral RNA stability and nascent viral RNA synthesis in the presence of miR-122

To investigate whether the significant reduction in C3U RNA abundance in the presence of miR-122 is a result of diminished RNA stability, Huh7.5 cells were transfected with HCV RNA

---

**Fig 4. Viral RNA stability and rates of replication in wild-type and C3U variants in the presence of miR-122.** (A) Effect of the C3U mutation on HCV RNA decay. Huh7.5 cells were transfected with wild-type and C3U H77.S3/GLuc RNA, treated with 25 μM of MK-0608 three days later, and viral RNA abundances were monitored at specific times after treatment, using Northern blot analyses. (B) One phase decay graph of HCV RNA (R² = 0.939–0.947) was determined by normalizing HCV RNA levels to loading control actin from three independent experiments. Estimated half-lives (t₁/₂) of wild-type and C3U RNA are 3.12 hours and 2.6 hours, respectively. (C) HCV RNA half-lives (t₁/₂) of three independent experiments (**p<0.0018). (D) Rates of RNA replication in wild-type and mutant HCV variant. Three days after HCV RNA transfection, RNA was labeled with 200 μM EU for 4 and 7 hours, conjugated to biotin and subsequently isolated with streptavidin beads. RNA replication rates were determined by RT-qPCR and data is normalized to wild-type HCV four hour labeling time point (**p<0.0047, ns = non-significant).

https://doi.org/10.1371/journal.ppat.1007467.g004
for three days and subsequently treated with the nucleoside analog MK-0608 to block viral RNA synthesis. Total RNA was isolated at the indicated time points following drug treatment and the rate of HCV RNA decay was examined by Northern blot analysis. Data showed that wild-type HCV RNA was degraded at a slightly slower rate than C3U mutant HCV RNA (Fig 4A). The approximate half-life of wild-type RNA is 3.2 hours compared to 2.6 hours for the C3U variant (Fig 4A and 4B). Although modest, the reduction in RNA stability was statistically significant (Fig 4C) and could potentially impact the fitness of the C3U virus.

Next, the effect of the C3U mutation on the rates of HCV RNA replication were evaluated by labeling cells with 5-EU three days post viral RNA transfection. Total RNA was isolated from cells pulsed for four and seven hours, captured and quantified as previously described. 5-EU-labeling for up to seven hours revealed a significant ~four-fold increase in the accumulation of newly-synthesized wild-type RNA compared to C3U variant RNA (Fig 4D). This impaired rate of RNA synthesis coupled with a modest, but significant decrease in RNA stability are likely sufficient to explain the reduced fitness of the C3U variant in the liver.

Effects of XRN1 depletion on HCV C3U RNA abundance

One explanation for the reduced abundance of C3U viral RNA during low abundance of miR-122 is that reduced binding of miR-122 at site 1 could render the RNA susceptible to attack by 5’ RNA triphosphatase DUSP11 [10] and subsequently to 5’-3’ exonucleases. Therefore, we investigated whether the low abundance of HCV C3U RNA variant of type 1a could be rescued by reducing the abundance of XRN1 by siRNA-mediated gene silencing prior to HCV RNA transfection. The effect of XRN1 depletion on HCV replication was assessed by luciferase activity and Northern blot analyses of chimeric RNAs. Robust XRN1 depletion was observed in mock- and HCV-infected samples at 72 hours after RNA transfection (Fig 5B, top panel). Depletion of XRN1 significantly stimulated the abundance of both wild-type and C3U HCV RNA at 48 and 72 hours after viral RNA transfection (Fig 5A). Similarly, increased accumulation of wild-type and C3U mutant HCV RNA was detected by Northern blot analysis in siXRN1-treated samples (Fig 5C). The effects of XRN1 depletion on wild-type HCV replication are consistent with previous observations using a similar HCV cell culture system [12]. Quantification indicated that wild-type and mutant viral RNA abundances significantly increased following XRN1 depletion by the same extent (Fig 5D). These data suggest that both wild-type and mutant HCV RNA are similarly susceptible to XRN1 attack and that the defect in C3U RNA replication is not increased degradation due to lack of miR-122 binding at site 1.

To explore the possibility that differences in miR-122 occupancy in the C3U variant could alter its susceptibility to XRN1 attack further, we tested the stability of the replication defective (GDD-to-AAG) wild-type and mutant HCV RNA synthesized with and without a 5’ non-methylated guanosine cap analog after transfection into Huh7.5 cells. Viral RNAs containing a cap structure or a 5’ terminal ppp-N moiety in C3U HCV displayed similar stabilities to that of wild-type RNA across multiple infection time points (Fig 5E). Data from both lines of investigation suggest that XRN1 is unlikely to explain the observed low C3U RNA abundance in Huh7 liver cells.

The C3U mutation residing in miR-122 site 1 seed sequence impairs formation of HCV:miR-122 heterotrimeric complex in vitro

The interaction between the 5’ noncoding region of HCV and miR-122 at sites 1 and 2 (Fig 6A) extends beyond the canonical base pairing between seed and seed-match sequences [6, 7]. Mutational analysis has shown that base pairing between HCV and miR-122 at nucleotides 1–4 produces a 3’ overhang in miR-122 that shields the viral genome from subsequent
exoribonuclease attack [7]. Also, previous observations indicate that the 5’ terminus of HCV forms a stable, trimolecular complex through interactions with the miR-122 at site 1 and 2 [25].

Adopting Mortimer’s and Doudna’s electrophoretic mobility shift assays (EMSA) approach [25], we investigated whether the C3U substitution disrupted the formation of the HCV:miR-122 heterotrimeric complex in solution. First, to confirm that the 5’ terminus of HCV genotype 1a (nucleotides 1–47) directly binds and forms an oligomeric complex with miR-122, wild-type HCV RNA was incubated with increasing amounts of miR-122 and the resulting complexes were resolved using EMSA. Fig 6B shows that incubation of HCV RNA with different molar equivalents of miR-122 resulted in the gradual formation of a heterotrimeric complex that migrated more slowly than free HCV RNA (Fig 6B, lane 0). Incubation of HCV RNA with the neuron-specific miRNA, miR-124, showed no complex formation, demonstrating
that the interaction between HCV and miR-122 is specific. Next, we investigated effects of the C3U mutation on the formation of the heterotrimeric complexes. Fig 6C shows that the C3U-containing RNA required a much higher concentration of miR-122 to form any heterotrimeric complexes. Fig 6. In vitro binding assays of HCV domain I nucleotides 1–47 with native and mutant miR-122 species. (A) Pairing interactions between two miR-122 molecules with 5’ RNA sequences of HCV genotype 1a (nucleotides 1–47). The position of the C3U nucleotide change is indicated. (B) HCV oligonucleotides were incubated with increasing concentrations of native miR-122 or the neuron-specific miR-124, and the resulting complexes were separated by native gel electrophoresis mobility shift assay. The migrations of free miRNA, one miR122-HCV complex (HCV :miR-122), and two miR-122-HCV complexes (HCV-miR-1222) are indicated. (C,D) Wild-type and C3U domain I RNAs were incubated with native miR-122 (C) or mutant miR-122 (D). (E) The seed-match sequence of miR-122 binding site 1 in wild-type and C3U RNAs was mutated and then incubated with increasing amounts of native miR-122. Resulting oligomeric complexes was resolved by non-denaturing gel electrophoresis. The data are representative of three independent replicates. Nucleic acids were visualized after staining with SYBR Gold (Thermo Fisher).

https://doi.org/10.1371/journal.ppat.1007467.g006
complex at all. To examine whether mut-miR-122 could rescue the formation of heterotrimeric complexes, wild-type or C3U RNAs were incubated with mut-miR-122 and complexes resolved by EMSA. Incubation of wild-type HCV RNA with mut-miR-122 resulted in diminished formation of the trimeric complex (Fig 6D). In contrast, formation of a trimolecular complex was observed after incubation of C3U RNA with mut-miR-122 (Fig 6D). These results show that mut-miR-122 can bind to both site 1 and 2 in C3U RNA, but only to high-affinity site 2 in wild-type RNA. Binding of mut-miR-122 to its target site is mediated by its interaction with the HCV RNA that extends beyond the seed-seed match interactions. To confirm that C3U RNA and miR-122 interact at binding site 2, the seed sequence of miRNA binding site 1 was mutated in both wild-type and C3U RNAs so that only site 2 was available for binding. Both RNAs did allow the formation of dimeric, but not trimeric complexes (Fig 6E), arguing that miR-122 can bind to site 2 in C3U RNA independently of site 1. These data suggest that a single C3U mutation outside the seed-match region of site 1 results in reduced binding of miR-122 to site 1 but allows binding of miR-122 to site 2, culminating in the formation of weak, unstable trimeric complexes. Indeed, it has been shown that miR-122 binding suppresses the folding of the 5' end of HCV RNA into more energetically favored structures [16].

The C3U mutated viral genome recruits a distinct set of proteins in live cells

How does the single C3U mutation contribute to enhanced RNA accumulation when miR-122 abundance is low? It is possible that the C3U mutations introduces structural changes at the 5’ end of the viral positive strand or the 3’ end of the viral negative strand that contribute to the C3U variant phenotype. This is however unlikely, because of in silico prediction and mutational analyses indicated that the C3U in the viral positive or the complementary negative strand RNA is not part of a secondary structure [16, 30–32]. Alternatively, the C3U could recruit a distinct set of proteins that aids in the amplification of the C3U RNA when miR-122 abundances are low. To examine this possibility, we analyzed the binding of proteins to wildtype and mutant RNA genomes in RNA-transfected cells. First, chimeric RNAs were generated in which the loop sequences in SL1 were altered to bind a fusion lambda-N-BirA’ ligase protein (Fig 7A) [33]. As expected [31], insertions at this position in SL1 were tolerated and gave rise to replicating RNAs (WT+BoxB, C3U+BoxB) after transfection of in vitro synthesized RNAs into cells. Western blot analyses showed that C3U+BoxB RNAs produced slightly less amount of viral proteins than WT+BoxB (Fig 7B). Next, biotin was added to transfected cells and biotinylated proteins were isolated after addition of streptavidin beads [33]. Biotinylated protein were then identified by mass spectrometry. Fig 7C lists the ten proteins that bound specifically to the C3U genome. We were intrigued that DDX6 was biotinylated in C3U-infected cells, because DDX6 has been implicated in HCV RNA amplification [34–36]. Thus, DDX6 was depleted by CRISPR/Cas9 and effects on WT and C3U RNA abundances were monitored. Fig 7D shows that the kinetics of RNA replication of WT and C3U RNAs were the same in DDX6-depleted cells. This phenotype was reversed after add-back of DDX6, arguing that DDX6 modulates C3U HCV amplification independently of mir-122 binding at site 1. Investigation of the other nine proteins in the life cycle of HCV is under scrutiny. The pathways in which some of these proteins are predicted to operate suggest roles for some of these proteins in lipid metabolism and intracellular compartmentalization during viral infection. Specifically, SHC1 has been identified to interact with HCV receptor CD81 [37] and siRNA-mediated depletion of SHC1 inhibits HCV entry [38]. Proteome-wide interaction studies has revealed that GOLGA2 interacts with NS5A [39]. Thus, SHC1 and GOLGA2 may modulate entry/egress or replication of C3U RNAs, respectively.
Fig 7. RNA-protein interaction detection (RAPID) approach to identify proteins that associate with C3U viral RNA in living cells. (A) Schematic overview of RAPID. Viral and miR-122 RNAs are depicted. Putative binding protein complexes are shown as ovals. See text for details. (B) Abundances of HCV core and cellular actin proteins in cell extracts isolated from non-transfected (NT) and viral RNA-transfected cells. A Western blot is shown. (C) List of biotinylated proteins that interact uniquely with the C3U-BoxB viral genome. Complete list of identified proteins can be found in the Excel File in the Appendix. (D) Kinetics of wildtype (WT) and mutant C3U (C3U) RNA abundances in RNA-transfected Huh7 cells containing (WT) or lacking (DDX6 KO) DDX6. Knock out and genetic complementation by DDX6 add back was described previously [42].

https://doi.org/10.1371/journal.ppat.1007467.g007
Discussion

Traditional antivirals have overwhelmingly focused on targeting virus-encoded proteins that are essential components of the viral life cycle using small molecule inhibitors. Due to the high mutation rates of RNA-dependent viral RNA polymerases, non-lethal mutations in the viral genome can result in drug-resistance phenotypes to these direct-acting antivirals. On the other hand, targeting the expression or function of host cellular factors that are vital for viral growth is predicted to result in a higher genetic barrier to resistance than direct-acting antivirals. The liver-expressed microRNA miR-122 was recently targeted in a miRNA-based anti-HCV therapeutic strategy. Pharmacological inhibition of miR-122 using modified anti-sense oligonucleotides (anti-miRs) significantly lowered the viral load in the serum of HCV-infected patients [20, 21].

A C3U resistance-associated mutation in the miR-122 binding site 1 of the HCV 5’ noncoding region was observed in sera from patients that experienced virologic rebound several weeks following treatment with miR-122 anti-miRs. However, late responders did not display the C3U mutation. In follow-up studies with 18 patients, 6 of them displayed the C3U mutation at the time of rebound, and the mutation disappeared in 3 of the 6 patients before they underwent standard-of-care treatment [21]. This led us to investigate whether this single C3U substitution conferred true resistance to the inhibitory effects of anti-miRs and, if so, by what mechanism viral replication could occur at lowered abundance of miR-122. While patient-derived virus did not grow in Huh7 cells, using a cell culture-adapted HCV genotype 1a infectious system we found that the C3U mutation, during sequestration of miR-122, showed an increased ability to replicate the C3U RNA compared to wild-type RNA. However, this came at the expense of significantly diminished viral fitness in liver cells with normal abundance of miR-122. Specifically, RNA stability and rates of RNA replication of the C3U RNA are impaired in cells that express normal amounts of miR-122. Curiously, the C3U mutation has not been observed during selection experiments in Huh7 cells [20, 27, 29] and no naturally occurring C3U HCV genotypes have been deposited into Gene bank. Ono et al. observed a viral G28A mutation that arose in the serum and peripheral blood monocytes of type 2-infected patients [29], however, the C3U variant has only been observed in patient serum after several weeks in anti-miR treatment, and only transiently. Whether the extrahepatic C3U genomes reflect growth of the C3U variant in the liver of re-bounding patients is not known, because liver biopsies are not available. However, the poor fitness of the C3U variants suggests that the C3U variant may contribute little to HCV-induced liver pathogenesis. This would be similar to the situation observed with sofosbuvir, i.e. during treatment of patients with this HCV polymerase inhibitor, selection is observed for variants whose fitness in the absence of the drug is so low that they do not persist [40].

What is the mechanism by which the C3U variant can replicate in the presence of low amounts of miR-122? Using genetic and biochemical approaches, we discovered that miR-122 binds only at site 2 in the C3U RNA. Using EMSA, Mortimer and Doudna showed that miR-122 binds at miRNA binding site 2 with an affinity 50-fold greater than at site 1 [25], explaining the continued binding of miR-122 at site 2 in C3U even when miR-122 abundance is low. Why can the C3U variant accumulate in extra-hepatic cells where miR-122 abundance is very low? It is possible that novel inter- or intramolecular RNA-RNA interactions lead to stabilization of the viral genomic RNA that contains the C3U mutation in the absence of miR-122. Novel RNA-protein interactions could also take place at the 5’ end of C3U RNAs. Indeed, cell-based biotinylation studies have revealed a set of proteins that specifically interact with the C3U genome. It will be important to identify which molecular interactions aid in the evolution of the C3U genome, and whether the C3U variant engages with a similar set of proteins in extracellular reservoirs during miR-122 anti-miR treatment.
Materials and methods

Cell culture
Huh7.5 Sec14L2 and Huh7.5 ΔmiR-122 cells (generous gifts from Charles Rice, Rockefeller University, New York) were maintained in DMEM supplemented with 10% FBS, 1% non-essential amino acids, and 2 mM L-glutamine (Gibco).

In-vitro synthesized RNA and transfection
Plasmids H77S.3 and H77S.3/GLuc genotype 1a [23] (generous gifts from Stan Lemon, University of North Carolina, North Carolina) were transcribed using the T7 MEGAscript kit (Ambion), according to the manufacturer’s instructions. Huh7.5 and Huh7.5 ΔmiR-122 cells, plated in 12-well dishes, were transfected with 1 μg of in vitro-transcribed (IVT) H77S.3/GLuc RNA using the TransIT mRNA transfection kit (Mirus Bio LLC) according to the manufacturer’s protocol. After 6 hours of incubation at 37˚C, supernatants were removed for GLuc assay and replaced with fresh media. Supernatants were subsequently collected at 24 hours intervals. Supernatants were stored at -20˚C before luciferase assay.

Fluorescent focus-forming assay
Infectious titers were determined by a fluorescent focus forming units (FFU) assay. Huh7.5 cells (3X10^4) were seeded in a 48-well plate and incubated overnight. Serial dilutions of virus stock were added to cells and incubated for six hours at 37˚C. The diluted virus supernatant was removed and replaced with fresh medium. Media in each plate were exchanged daily. At day three post-infection, cells were washed once with PBS and fixed with cold methanol/acetone (1:1). HCV infection was analyzed by using a mouse monoclonal antibody directed against HCV core (Abcam) at 1:300 dilution in 1% fish gelatin/PBS at room temperature for two hours and an AlexFluor488-conjugated goat anti-mouse antibody (Invitrogen) at 1:200 dilution at room temperature for 1 hour. The fluorescent focus forming units were counted using a fluorescence microscope.

Antisense oligonucleotides
Antisense miR-122 locked nucleic acid (LNA) and RG101 have been previously described [18, 21].

Viral RNA quantification using a Cell-to-Ct q-RT-PCR method
3,000 Huh7.5 cells were seeded in quadruplicates in a 96-well plate one day prior to infection. The following day, cells were infected with wild-type and C3U virus at an MOI of 0.005. Six hours post infection, media was aspirated and replaced with fresh media. Media was replaced with fresh media every day. At the indicated time post-infection, cells were lysed using the Power SYBR Green Cell-to-Ct kit (Ambion), and RNAs were quantified on a Bio-rad CFX Connect quantitative-PCR (qPCR) machine and Ct values were normalized to internal control 18S ribosomal RNA expression values. The primer sequences for the HCV H77.S3 genotype were: forward 5’- CCAACTGATCAACACCAACG -3’ and reverse 5’- AGCTGGTCAACCTCTCAGGA -3’. The primer sequences for human 18S rRNA gene were: forward 5’- AGAAA CGGCTACCACATCCA -3’ and reverse 5’- CACCAGACTTGCCCTCCA -3’.

Exogenous miR-122 supplementation assay
Huh7.5 ΔmiR-122 cells were plated in 12-well dishes and transfected with annealed native miR-122 and mut-miR-122 duplexes (50nM) alone or in combination using Dharmafect I
(Dharmacon) following the manufacturer’s instruction. The following day, cells were transfected with 1 μg H77 GLuc IVT RNA as stated above. Twenty-four hours post H77 RNA transfection, cells were re-supplemented with 50nM of native or mut-miR-122. Supernatants from transfected cells were collected at the indicated time points. The following oligonucleotides were used in this study: native miR-122, 5'- UGGAGUGUGACAA UGGUGUUUGU-3'; mut-miR-122, 5'-UGGAGUGUGACA AUAGUGUUUGU-3'; hsa-miR-106b, 5'- UAAAGUGCU GACAGUGCA-3'.

Nucleoside analogue MK-0608 treatment
Huh7.5 cells, plated in 60mm dishes, were transfected with 2 μg of H77 GLuc IVT RNA as stated above. Three days post-transfection, media was removed and replaced with media containing MK-0608 at a final concentration of 25 μM. RNA was collected at the indicated time points and HCV RNA was analyzed by Northern blot analysis. RNA half-lives were calculated from three independent experiments using GraphPad Prism.

In vitro RNA capping reactions
Fifty micrograms of IVT H77 WT GLuc-AAG and H77 C3U GLuc-AAG RNAs were capped using the ScriptGap m7G Capping System (Cellscript C-SCC30610) according to the manufacturer’s protocol. RNA was extracted using the RNeasy Mini kit (QIAGEN) following the manufacturer’s instructions. Purified RNA was transfected into Huh7.5 cells and samples were collected at the indicated time points.

Luciferase activity assays
Following RNA transfection, secreted GLuc activity was measured in 20 μl aliquots from supernatants using the Luciferase Assay System (Promega), according to the manufacturer’s instructions. The luminescent readings were taken using Glomax 20/20 luminometer using a 10 second integration time.

Generation of H77S.3 virus
Virus production was done as previously described [41]

H77S.3 and H77S.3/GLuc mutant generation
Nucleotide substitutions to pH77S.3 and pH77S.3/GLuc were completed using the QuickChange Site Directed Mutagenesis Kit (Agilent), according to the manufacturer’s protocol.

For the C3U mutation, the following primers were utilized: 5’-ACGACTCAGATA GGCGCCACGACCACACACCGACGATG-3’ and 5’- CCCATCGAAGCGTAGGCTATAGTGAGTCGTTTATCTTG-3’. To introduce the lethal mutation to the NS5B polymerase (GDD > AAG), the following primers were used: 5’-CCATGCTGCTG TGTGCCGCTGACGCTGATGGG-3’ and 5’-CAGAGATGCGACTAAGCCGGCGACACAGGACGATG-3’.

Small interfering RNA transfections
For XRN1-mediated depletion, the following RNAs were utilized: sense 5’-GAGGUGUUGUU UCAGCAGAUUdTdT-3’ and antisense 5’-AAATGCGAAACAACACCTCdTdT-3’. Sense and antisense strands were combined in 1X siRNA Buffer (Dharmacon) at a final concentration of 20 μM, denatured for 2 minutes at 98˚C, and annealed for 1 hour at 37˚C. As a negative control siRNA, the following oligonucleotides were used: sense 5’- GAUCAUCGUGCGAU CAGAdTdT-3’ and antisense 5’-UCUGAUCGACGUAUGAUCdTdT-3’. 
Huh7.5 cells were seeded overnight in 12 well plates. The following day, 50 nM of siRNA duplexes were transfected using Dharmafect I (Dharmacon). Following overnight incubation at 37°C, cells were transfected with H77S.3/GLuc, supernatants were collected at the indicated time points and total RNA was extracted 3 days post-transfection. Depletion of XRN1 was assessed by western blot analysis.

**Western blot analysis**

Cells transfected for 3 days were washed with PBS once and lysed in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, and 1% Triton X-100) in the presence of complete™, EDTA-free protease inhibitor cocktail (Roche) for 30 min on ice. Lysates were clarified to remove the non-soluble fraction by centrifugation at 14,000 rpm for 10 min at 4°C. Protein concentrations were measured by Bradford Assay and 50 μg of total protein lysate was mixed with 5X protein sample buffer containing reducing agent. Samples were separated on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane (Millipore), and blocked with 5% non-fat milk in PBS-T. The following primary antibodies were used to probe the membranes: anti-Core (C7-50) (Abcam, ab2740), anti-Actin (Sigma), and anti-XRN1 (Bethyl Lab A300-443A.) Immunoblots were developed using Pierce ECL Western Blot Substrate (Thermo Fisher) following the manufacturer’s suggested instructions.

**RNA isolation and Northern blot analysis**

Total RNA was extracted using the RNeasy Mini kit (QIAGEN). For Northern blot analysis of HCV and actin RNA, 10 μg of total RNA in RNA loading buffer (32% formamide, 1X MOPS-EDTA-Sodium acetate (MESA, Sigma), and 4.4% formaldehyde) was denatured for 10 minutes at 65°C, separated in a 1% agarose gel containing 1X MESA and 3.7% formaldehyde, transferred and UV-crosslinked to a Zeta-probe membrane (Bio-Rad) overnight. The membrane was blocked and hybridized using ExpressHyb hybridization buffer (Clontech) and α-32P dATP-RadPrime DNA labeled probes.

**Nascent HCV RNA labeling**

Nascent HCV RNA transcripts were quantified using the Click-iT Nascent RNA Capture Kit (Thermo Fisher) following the manufacturer’s instructions. Complementary DNA was synthesized using Superscript III reverse transcriptase (Thermo Fisher) following the manufacturer’s protocol. Newly synthesized HCV transcripts were quantified using Power SYBR Green PCR Master Mix (Thermo Fisher). HCV transcript abundances were determined by comparisons to standard curves obtained from in vitro transcribed H77.S3 RNA. The primer sequences for the HCV H77.S3 genotype were: forward 5’- CGTGTGCTGCTCAATGTCTT -3’ and reverse 5’- AATGGCTGTCCAGAACACTTG -3’. Newly C3U HCV synthesized RNA abundances were represented as fold change relative to EU labeling of wild-type HCV RNA.

**HCV-miR-122 electrophoretic mobility shift assays (EMSA)**

Wild-type and mutant HCV RNA oligonucleotides corresponding to H77S.3 domain I (nucleotides 1–47) were synthesized (Stanford PAN facility). HCV domain I RNA (5 μ) was mixed with 100 mM HEPES (pH 7.5), 100 mM KCl, and 5mM MgCl₂ in a 5 μl reaction. Reactions were heated to 98°C for 3 min, cooled to 35°C for 5 min, and incubated with miR-122 oligos in molar ratios of 0.5, 1, 2, 3, and 4 at 37°C for 30 min. For anti-miR experiments, 1 μl of miR-122 antisense oligonucleotide was added to each reaction and incubated for an additional 10 minutes. Five μl of RNA loading dye (30% glycerol, 0.5X TBE and 6mM MgCl₂) was added
and samples were separated in a non-denaturing gel (12% 29:1 acrylamide:bisacrylamide, 0.5X TBE and 6mM MgCl₂) at 4˚C for 2.5 hours at 20 Amps. Gel was stained with SYBR Gold (Invitrogen) to visualize the HCV RNA-miR-122 interactions.

**RNA-protein interaction detection (RAPID) to identify protein-HCV RNA interactions**

Wildtype and C3U H77.S3 IRES stem-loop I was mutated to the BoxB RNA motif sequence 5’-GCCCTGAAAAGGGC-3’ [33] using the QuickChange Site Directed Mutagenesis Kit (Agilent), according to the manufacturer’s protocol. Huh7.5 cells were then transfected with 10 μg wildtype, wildtype-BoxB, C3U, or C3U-BoxB in-vitro synthesized RNA using the TransIT mRNA transfection kit (Mirus Bio LLC) according to the manufacturer’s protocol. Six hours after incubation at 37˚C, media was removed and replaced with fresh media. After 48 hour incubation, 4 μg of BirA+ RaPID plasmid [33] was transfected into H77.S3-transfected cells using Lipofectamine 2000 following the manufacturer’s instructions. Two days post-transfection, media was aspirated and replaced with 50μM biotin (Sigma-Aldrich) labeling media diluted with DMEM (Thermo-Fisher Scientific), and incubated for 16 hours at 37˚C. Media was then aspirated and cells were washed with cold 1X PBS. After addition of 0.6 ml of cell lysis buffer (0.5M NaCl, 50mM Tris-HCl, 0.2% SDS, 1mM DTT), lysates were scraped and transferred into individual Eppendorf tubes and placed on ice. Next, 52 μl of Triton-X-100 (Sigma-Aldrich) was mixed with the lysates, followed by addition of 0.65 ml of wash buffer 4 (50mM Tris-HCl). Samples were subsequently sonicated at intervals of 10 seconds until lysate was clear. In between sonication cycles, samples were cooled on ice for 10 seconds. Insoluble material was removed by sedimenting samples at 15,000 g at 4˚C for 10 minutes. Unincorporated biotin was removed by centrifuging the cleared supernatant in Macrosep Advance Spin Filter 3K MWCO tubes (VWR) and centrifuged at 1,500 g at 4˚C for 1 hour. Supernatants were transferred to an Eppendorf tube and protein concentration was estimated using the Bradford assay. To retrieve biotin-labelled proteins, MyOne C1 Streptavidin beads (Life Technologies) were added overnight at 4˚C in a rotator. The following day, tubes were placed on a magnetic stand and supernatants aspirated. To each sample, 1 ml of wash buffer 1 (2% SDS) was added and rotated for 5 minutes at room temp. This washing step was repeated two times. Next, supernatants were aspirated and 1 ml wash buffer 2 (0.1% Na-DOC, 1% Triton X-100, 0.5M NaCl, 50mM HEPES pH 7.5, 1mM EDTA) was added and rotated for 5 minutes at room temperature. Magnetic beads were washed using 1 ml wash buffer 3 (0.5% Na-DOC, 250μM LiCl, 0.5% NP-40, 10mM Tris-HCl, 1mM EDTA), followed by a wash with 1ml of buffer 4 (50mM Tris-HCl). All residual supernatant was removed and washed beads were directly submitted to the Stanford Mass Spectrometry facility for protein identification, and data analysis was performed as described by Ramanathan et al. [33]. Protein IDs can be seen in the attached Microsoft Excel file.

**Statistical analysis**

Statistical analyses were performed with Prism 5 (GraphPad). A two-tailed paired Student’s t-test was employed to assess significant differences between two groups. Error bars represent standard error of the mean.

**Supporting information**

S1 Fig. Effects of miR-122 sequestration using miR-106 LNA, miR-122-LNA or RG1649 anti-miRs. Shown are the non-normalized data from Fig 1B. Viral RNA replication was
measured by luciferase production at the indicated time points.

(TIF)

S2 Fig. Effect of C3U mutations in J6/JHF1 viral background. Huh7.5 cells were transfected with wild-type or C3U J6/JFH1 RLuc genomes and RNA replication was determined at the indicated time points. P values are < 0.0001.

(TIF)

S3 Fig. Effect of C3U and G28A mutations in J6/JHF1 viral background. Huh7.5 cells were transfected with chimeric J6/JFH1 RLuc genomes and RNA replication was determined at the indicated time points. P values are < 0.0001.

(TIF)

S4 Fig. Polysomal association of C3U HCV variant. (A) HCV RNA distribution across a sucrose gradient was determined three days following transfection of Huh7.5 cells with wild-type and C3U H77.S3/GLuc RNAs. Polysomal profile trace of lysates separated in 10–60% sucrose gradients. Individual subunits, monosomal, and polysomal peaks are indicated (top). Detection of HCV and actin RNA in sucrose fractions 2 through 13 by Northern blot analysis (middle). Small (S6 rp) and large (L13a rp) ribosomal protein abundances detected by Western blot of total protein isolated from input (6%) and from fractions 4 through 13 (bottom). (B) Percent of HCV RNA distributed across the polysomal gradients of three independent experiments. Error bars display +/- SD.

(TIF)

S1 File. WT_BoxB_protein list.

(XLSX)

S1 Methods. Supplemtal methods.

(DOCX)

Acknowledgments

We are grateful to Karla Kirkegaard for many helpful comments. The gifts of Huh7.5 Sec14L2 and Huh7.5 ΔmiR-122 cells from Joseph Luna and Charles Rice (Rockefeller University, NY) are gratefully acknowledged. We are indebted to Stan Lemon (University of North Carolina, NC) for receiving plasmids H77S.3 and H77S.3/GLuc genotype 1a.

Author Contributions

Conceptualization: Miguel Mata, Steven Neben, Jan Carette, Muthukumar Ramanathan, Peter Sarnow.

Data curation: Miguel Mata, Steven Neben, Karim Majzoub.

Formal analysis: Miguel Mata, Karim Majzoub, Jan Carette, Muthukumar Ramanathan, Paul A. Khavari, Peter Sarnow.

Funding acquisition: Peter Sarnow.

Investigation: Miguel Mata, Karim Majzoub, Peter Sarnow.

Methodology: Miguel Mata, Karim Majzoub, Peter Sarnow.

Project administration: Peter Sarnow.

Resources: Miguel Mata, Steven Neben, Peter Sarnow.
Software: Miguel Mata.
Supervision: Jan Carette, Peter Sarnow.
Validation: Miguel Mata.
Writing – original draft: Miguel Mata, Peter Sarnow.
Writing – review & editing: Miguel Mata, Steven Neben, Karim Majzoub, Jan Carette, Muthukumar Ramathan, Paul A. Khavari, Peter Sarnow.

References

1. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015; 16(7):421–33. https://doi.org/10.1038/nrg3965 PMID: 26077373.

2. Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015; 22(1):22–33. https://doi.org/10.1038/cdd.2014.112 PMID: 25190144; PubMed Central PMCID: PMCPMC4262769.

3. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309(5740):1577–81. https://doi.org/10.1126/science.1113329 PMID: 16410476.

4. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pearson M, et al. mir-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3(2):87–98. https://doi.org/10.1016/j.cmet.2006.01.005 PMID: 16459310.

5. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005; 438(7068):685–9. https://doi.org/10.1038/nature04303 PMID: 16258535.

6. Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008; 4(1):77–85. https://doi.org/10.1016/j.chom.2008.05.013 PMID: 18621012; PubMed Central PMCID: PMCPMC2903297.

7. Machlin ES, Sarnow P, Sagan SM. Masking the 5’ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011; 108(8):3193–8. https://doi.org/10.1073/pnas.1012464108 PMID: 21220300; PubMed Central PMCID: PMCPMC3044371.

8. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol. 2010; 84(13):6615–25. Epub 2010/04/30. https://doi.org/10.1128/JVI.00417-10 PMID: 20427583; PubMed Central PMCID: PMCPMC2903297.

9. Chang J, Nicolas E, Marks D, Sander C, Lerdo A, Buendia MA, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004; 1(2):106–13. PMID: 17179747.

10. Kincaid RP, Lam VL, Chirayil RP, Randall G, Sullivan CS. RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus. Proc Natl Acad Sci U S A. 2011; 108(32):18197–202. Epub 2010/07/25. https://doi.org/10.1073/pnas.1017841108 PMID: 30038017; PubMed Central PMCID: PMCPMC6094126.

11. Amador-Canizares Y, Bernier A, Wilson JA, Sagan SM. miR-122 does not impact recognition of the HCV genome by innate sensors of RNA but rather protects the 5’ end from the cellular pyrophosphatas, DOM3Z and DUSP11. Nucleic Acids Res. 2018. https://doi.org/10.1093/nar/gky273 PMID: 29672716.

12. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A. 2013; 110(5):1881–6. https://doi.org/10.1073/pnas.1213515110 PMID: 23248316; PubMed Central PMCID: PMCPMC3582843.

13. Sedano CD, Sarnow P. Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe. 2014; 16(2):257–64. https://doi.org/10.1016/j.chom.2014.07.006 PMID: 25121753; PubMed Central PMCID: PMCPMC4227615.

14. Henke JT, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008; 27(24):3300–10. Epub 2008/11/21. https://doi.org/10.1038/emboj.2008.244 PMID: 19020517; PubMed Central PMCID: PMCPMC2586803.

15. Roberts AP, Lewis AP, Jopling CL. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 2011; 39(17):7716–29. Epub
miR-122 independent growth of HCV C3U mutant

2011/06/10. https://doi.org/10.1093/nar/gkr426 PMID: 21653556; PubMed Central PMCID: PMC3177192.

16. Schult P, Roth H, Adams RL, Mas C, Imbert L, Ortik C, et al. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun. 2018; 9(1):2813. Epub 2018/07/06. https://doi.org/10.1038/s41467-018-05053-3 PMID: 29973597; PubMed Central PMCID: PMC6036965.

17. Masaki T, Arend KC, Li Y, Yamane D, McGivern DR, Kato T, et al. miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe. 2015; 17(2):217–28. https://doi.org/10.1016/j.chom.2014.12.014 PMID: 25662750; PubMed Central PMCID: PMC4326553.

18. Schult P, Roth H, Adams RL, Mas C, Imbert L, Ortik C, et al. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun. 2018; 9(1):2813. Epub 2018/07/06. https://doi.org/10.1038/s41467-018-05053-3 PMID: 29973597; PubMed Central PMCID: PMC6036965.

19. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

20. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017; 389(10070):709–17. https://doi.org/10.1016/S0140-6736(16)31715-9 PMID: 28087069.

21. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

22. Masaki T, Arend KC, Li Y, Yamane D, McGivern DR, Kato T, et al. miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe. 2015; 17(2):217–28. https://doi.org/10.1016/j.chom.2014.12.014 PMID: 25662750; PubMed Central PMCID: PMC4326553.

23. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

24. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017; 389(10070):709–17. https://doi.org/10.1016/S0140-6736(16)31715-9 PMID: 28087069.

25. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

26. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

27. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.

28. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015; 59(1):599–608. https://doi.org/10.1128/AAC.00220-14 PMID: 25385103; PubMed Central PMCID: PMC4291405.
33. Ramanathan M, Majzoub K, Rao DS, Neela PH, Zarnegar BJ, Mondal S, et al. RNA-protein interaction detection in living cells. Nat Methods. 2018; 15(3):207–12. Epub 2018/02/06. https://doi.org/10.1038/nmeth.4601 PMID: 29400715; PubMed Central PMCID: PMCPMC5886736.

34. Pager CT, Schutz S, Abraham TM, Luo G, Sarnow P. Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules. Virology. 2013; 435(2):472–84. Epub 2012/11/13. https://doi.org/10.1016/j.virol.2012.10.027 PMID: 23141719; PubMed Central PMCID: PMCPMC3534916.

35. Biegel JM, Henderson E, Cox EM, Bonenfant G, Netzeband R, Kahn S, et al. Cellular DEAD-box RNA helicase DDx6 modulates interaction of miR-122 with the 5’ untranslated region of hepatitis C virus RNA. Virology. 2017; 507:231–41. Epub 2017/04/30. https://doi.org/10.1016/j.virol.2017.04.014 PMID: 28456022; PubMed Central PMCID: PMCPMC5549679.

36. Huys A, Thibault PA, Wilson JA. Modulation of hepatitis C virus RNA accumulation and translation by DDx6 and miR-122 are mediated by separate mechanisms. PLoS One. 2013; 8(6):e67437. Epub 2013/07/05. https://doi.org/10.1371/journal.pone.0067437 PMID: 23826300; PubMed Central PMCID: PMCPMC3691176.

37. Bruening J, Lasswitz L, Banse P, Kahl S, Marinach C, Vondran FW, et al. Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathog. 2018; 14(7): e1007111. Epub 2018/07/20. https://doi.org/10.1371/journal.ppat.1007111 PMID: 30024968; PubMed Central PMCID: PMCPMC6053247.

38. Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe. 2013; 13(3):302–13. Epub 2013/03/19. https://doi.org/10.1016/j.chom.2013.02.006 PMID: 23498955.

39. de Chassy B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugue S, et al. Hepatitis C virus infection protein network. Mol Syst Biol. 2008; 4:230. Epub 2008/11/06. https://doi.org/10.13038/msb.2008.66 PMID: 18985028; PubMed Central PMCID: PMCPMC2600670.

40. Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, et al. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. J Infect Dis. 2016; 213(8):1240–7. Epub 2015/11/26. https://doi.org/10.1093/infdis/jiv564 PMID: 26603202.

41. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, et al. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med. 2014; 20(8):927–35. https://doi.org/10.1038/nm.3610 PMID: 25064127; PubMed Central PMCID: PMCPMC4126843.

42. Lumb JH, Li Q, Popov LM, Ding S, Keith MT, Merrill BD, et al. DDx6 Represses Aberrant Activation of Interferon-Stimulated Genes. Cell Rep. 2017; 20(4):819–31. Epub 2017/07/27. https://doi.org/10.1016/j.celrep.2017.06.085 PMID: 28746868; PubMed Central PMCID: PMCPMC5551412.